Clinical and Regulatory Update
At its fourth quarter earnings conference call, Acadia Pharmaceuticals (NASDAQ:ACAD) provided an update on its clinical and regulatory programs. These include the ongoing stability testing of the three registration batches of pimavanserin produced in the third quarter of 2013, the ongoing drug-drug interaction studies, the ongoing accumulation of data from the -015 extension study, and the Phase 2 Alzheimer's Disease Psychosis (ADP) trial.
The registration stability testing is designed to comply with ICH guidelines and to meet the regulatory filing requirements for major markets worldwide. As expected, the company now has the initial three months of stability on the registration lots of pimavanserin, and the data appears to be consistent with what was seen...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|